Jane Endicitt’s Publications

  1. Tatum, NJ, Endicott, JA. Chatterboxes: the structural and functional diversity of cyclins. Semin. Cell Dev. Biol. 2020; :. doi: 10.1016/j.semcdb.2020.04.021. PubMed PMID:32414682 .
  2. Myers, SM, Miller, DC, Molyneux, L, Arasta, M, Bawn, RH, Blackburn, TJ et al.. Identification of a novel orally bioavailable ERK5 inhibitor with selectivity over p38α and BRD4. Eur J Med Chem. 2019;178 :530-543. doi: 10.1016/j.ejmech.2019.05.057. PubMed PMID:31212132 .
  3. Rappaport, SH, Endicott, JA, Gilbert, MP, Farkas, JD, Clouser, RD, McMillian, WD et al.. A Retrospective Study of Early vs Delayed Home Dose Basal Insulin in the Acute Management of Diabetic Ketoacidosis. 2019;3 (5):1079-1086. doi: 10.1210/js.2018-00400. PubMed PMID:31069278 PubMed Central PMC6500796.
  4. Wood, DJ, Lopez-Fernandez, JD, Knight, LE, Al-Khawaldeh, I, Gai, C, Lin, S et al.. FragLites-Minimal, Halogenated Fragments Displaying Pharmacophore Doublets. An Efficient Approach to Druggability Assessment and Hit Generation. J. Med. Chem. 2019;62 (7):3741-3752. doi: 10.1021/acs.jmedchem.9b00304. PubMed PMID:30860382 .
  5. Wood, DJ, Korolchuk, S, Tatum, NJ, Wang, LZ, Endicott, JA, Noble, MEM et al.. Differences in the Conformational Energy Landscape of CDK1 and CDK2 Suggest a Mechanism for Achieving Selective CDK Inhibition. Cell Chem Biol. 2019;26 (1):121-130.e5. doi: 10.1016/j.chembiol.2018.10.015. PubMed PMID:30472117 PubMed Central PMC6344228.
  6. Wood, DJ, Endicott, JA. Structural insights into the functional diversity of the CDK-cyclin family. Open Biol. 2018;8 (9):. doi: 10.1098/rsob.180112. PubMed PMID:30185601 PubMed Central PMC6170502.
  7. Miller, DC, Martin, MP, Adhikari, S, Brennan, A, Endicott, JA, Golding, BT et al.. Identification of a novel ligand for the ATAD2 bromodomain with selectivity over BRD4 through a fragment growing approach. Org. Biomol. Chem. 2018;16 (11):1843-1850. doi: 10.1039/c8ob00099a. PubMed PMID:29469144 PubMed Central PMC6102691.
  8. Martin, MP, Endicott, JA, Noble, MEM. Structure-based discovery of cyclin-dependent protein kinase inhibitors. Essays Biochem. 2017;61 (5):439-452. doi: 10.1042/EBC20170040. PubMed PMID:29118092 PubMed Central PMC6248306.
  9. Hallett, ST, Pastok, MW, Morgan, RML, Wittner, A, Blundell, KLIM, Felletar, I et al.. Differential Regulation of G1 CDK Complexes by the Hsp90-Cdc37 Chaperone System. Cell Rep. 2017;21 (5):1386-1398. doi: 10.1016/j.celrep.2017.10.042. PubMed PMID:29091774 PubMed Central PMC5681435.
  10. Coxon, CR, Anscombe, E, Harnor, SJ, Martin, MP, Carbain, B, Golding, BT et al.. Cyclin-Dependent Kinase (CDK) Inhibitors: Structure-Activity Relationships and Insights into the CDK-2 Selectivity of 6-Substituted 2-Arylaminopurines. J. Med. Chem. 2017;60 (5):1746-1767. doi: 10.1021/acs.jmedchem.6b01254. PubMed PMID:28005359 PubMed Central PMC6111440.
  11. Gaviola, ML, McMillian, WD, Ames, SE, Endicott, JA, Alston, WK. A Retrospective Study on the Protective Effects of Topical Vancomycin in Patients Undergoing Multilevel Spinal Fusion. Pharmacotherapy. 2016;36 (1):19-25. doi: 10.1002/phar.1678. PubMed PMID:26749522 .
  12. Anscombe, E, Meschini, E, Mora-Vidal, R, Martin, MP, Staunton, D, Geitmann, M et al.. Identification and Characterization of an Irreversible Inhibitor of CDK2. Chem. Biol. 2015;22 (9):1159-64. doi: 10.1016/j.chembiol.2015.07.018. PubMed PMID:26320860 PubMed Central PMC4579270.
  13. Brown, NR, Korolchuk, S, Martin, MP, Stanley, WA, Moukhametzianov, R, Noble, MEM et al.. CDK1 structures reveal conserved and unique features of the essential cell cycle CDK. Nat Commun. 2015;6 :6769. doi: 10.1038/ncomms7769. PubMed PMID:25864384 PubMed Central PMC4413027.
  14. Echalier, A, Hole, AJ, Lolli, G, Endicott, JA, Noble, ME. An inhibitor's-eye view of the ATP-binding site of CDKs in different regulatory states. ACS Chem. Biol. 2014;9 (6):1251-6. doi: 10.1021/cb500135f. PubMed PMID:24669831 PubMed Central PMC4068217.
  15. Carbain, B, Paterson, DJ, Anscombe, E, Campbell, AJ, Cano, C, Echalier, A et al.. 8-Substituted O(6)-cyclohexylmethylguanine CDK2 inhibitors: using structure-based inhibitor design to optimize an alternative binding mode. J. Med. Chem. 2014;57 (1):56-70. doi: 10.1021/jm401555v. PubMed PMID:24304238 .
  16. Anil, B, Riedinger, C, Endicott, JA, Noble, ME. The structure of an MDM2-Nutlin-3a complex solved by the use of a validated MDM2 surface-entropy reduction mutant. Acta Crystallogr. D Biol. Crystallogr. 2013;69 (Pt 8):1358-66. doi: 10.1107/S0907444913004459. PubMed PMID:23897459 .
  17. Endicott, JA, Noble, ME. Structural characterization of the cyclin-dependent protein kinase family. Biochem. Soc. Trans. 2013;41 (4):1008-16. doi: 10.1042/BST20130097. PubMed PMID:23863171 .
  18. Shao, H, Shi, S, Huang, S, Hole, AJ, Abbas, AY, Baumli, S et al.. Substituted 4-(thiazol-5-yl)-2-(phenylamino)pyrimidines are highly active CDK9 inhibitors: synthesis, X-ray crystal structures, structure-activity relationship, and anticancer activities. J. Med. Chem. 2013;56 (3):640-59. doi: 10.1021/jm301475f. PubMed PMID:23301767 PubMed Central PMC3579313.
  19. Hole, AJ, Baumli, S, Shao, H, Shi, S, Huang, S, Pepper, C et al.. Comparative structural and functional studies of 4-(thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile CDK9 inhibitors suggest the basis for isotype selectivity. J. Med. Chem. 2013;56 (3):660-70. doi: 10.1021/jm301495v. PubMed PMID:23252711 PubMed Central PMC3579457.
  20. Baumli, S, Hole, AJ, Wang, LZ, Noble, ME, Endicott, JA. The CDK9 tail determines the reaction pathway of positive transcription elongation factor b. Structure. 2012;20 (10):1788-95. doi: 10.1016/j.str.2012.08.011. PubMed PMID:22959624 PubMed Central PMC3469819.
  21. Boehringer, J, Riedinger, C, Paraskevopoulos, K, Johnson, EO, Lowe, ED, Khoudian, C et al.. Structural and functional characterization of Rpn12 identifies residues required for Rpn10 proteasome incorporation. Biochem. J. 2012;448 (1):55-65. doi: 10.1042/BJ20120542. PubMed PMID:22906049 PubMed Central PMC3481250.
  22. Endicott, JA, Noble, ME, Johnson, LN. The structural basis for control of eukaryotic protein kinases. Annu. Rev. Biochem. 2012;81 :587-613. doi: 10.1146/annurev-biochem-052410-090317. PubMed PMID:22482904 .
  23. Baumli, S, Hole, AJ, Noble, ME, Endicott, JA. The CDK9 C-helix exhibits conformational plasticity that may explain the selectivity of CAN508. ACS Chem. Biol. 2012;7 (5):811-6. doi: 10.1021/cb2004516. PubMed PMID:22292676 PubMed Central PMC3355656.
  24. Watson, AF, Liu, J, Bennaceur, K, Drummond, CJ, Endicott, JA, Golding, BT et al.. MDM2-p53 protein-protein interaction inhibitors: a-ring substituted isoindolinones. Bioorg. Med. Chem. Lett. 2011;21 (19):5916-9. doi: 10.1016/j.bmcl.2011.07.084. PubMed PMID:21875801 .
  25. Hardcastle, IR, Liu, J, Valeur, E, Watson, A, Ahmed, SU, Blackburn, TJ et al.. Isoindolinone inhibitors of the murine double minute 2 (MDM2)-p53 protein-protein interaction: structure-activity studies leading to improved potency. J. Med. Chem. 2011;54 (5):1233-43. doi: 10.1021/jm1011929. PubMed PMID:21314128 .
  26. Riedinger, C, Noble, ME, Wright, DJ, Mulks, F, Hardcastle, IR, Endicott, JA et al.. Understanding small-molecule binding to MDM2: insights into structural effects of isoindolinone inhibitors from NMR spectroscopy. Chem Biol Drug Des. 2011;77 (5):301-8. doi: 10.1111/j.1747-0285.2011.01091.x. PubMed PMID:21244642 .
  27. Baumli, S, Endicott, JA, Johnson, LN. Halogen bonds form the basis for selective P-TEFb inhibition by DRB. Chem. Biol. 2010;17 (9):931-6. doi: 10.1016/j.chembiol.2010.07.012. PubMed PMID:20851342 .
  28. Trempe, JF, Brown, NR, Noble, ME, Endicott, JA. A new crystal form of Lys48-linked diubiquitin. Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun. 2010;66 (Pt 9):994-8. doi: 10.1107/S1744309110027600. PubMed PMID:20823512 PubMed Central PMC2935213.
  29. Riedinger, C, Boehringer, J, Trempe, JF, Lowe, ED, Brown, NR, Gehring, K et al.. Structure of Rpn10 and its interactions with polyubiquitin chains and the proteasome subunit Rpn12. J. Biol. Chem. 2010;285 (44):33992-4003. doi: 10.1074/jbc.M110.134510. PubMed PMID:20739285 PubMed Central PMC2962499.
  30. Bettayeb, K, Baunbæk, D, Delehouze, C, Loaëc, N, Hole, AJ, Baumli, S et al.. CDK Inhibitors Roscovitine and CR8 Trigger Mcl-1 Down-Regulation and Apoptotic Cell Death in Neuroblastoma Cells. 2010;1 (4):369-80. doi: 10.1177/1947601910369817. PubMed PMID:21779453 PubMed Central PMC3092200.
  31. Echalier, A, Endicott, JA, Noble, ME. Recent developments in cyclin-dependent kinase biochemical and structural studies. Biochim. Biophys. Acta. 2010;1804 (3):511-9. doi: 10.1016/j.bbapap.2009.10.002. PubMed PMID:19822225 .
  32. Takaki, T, Echalier, A, Brown, NR, Hunt, T, Endicott, JA, Noble, ME et al.. The structure of CDK4/cyclin D3 has implications for models of CDK activation. Proc. Natl. Acad. Sci. U.S.A. 2009;106 (11):4171-6. doi: 10.1073/pnas.0809674106. PubMed PMID:19237555 PubMed Central PMC2657433.
  33. Riedinger, C, Endicott, JA. All change: protein conformation and the ubiquitination reaction cascade. 2009;1 :19. doi: 10.3410/B1-19. PubMed PMID:20948667 PubMed Central PMC2920667.
  34. Riedinger, C, Endicott, JA, Kemp, SJ, Smyth, LA, Watson, A, Valeur, E et al.. Analysis of chemical shift changes reveals the binding modes of isoindolinone inhibitors of the MDM2-p53 interaction. J. Am. Chem. Soc. 2008;130 (47):16038-44. doi: 10.1021/ja8062088. PubMed PMID:18959403 .
  35. Bettayeb, K, Oumata, N, Echalier, A, Ferandin, Y, Endicott, JA, Galons, H et al.. CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases. Oncogene. 2008;27 (44):5797-807. doi: 10.1038/onc.2008.191. PubMed PMID:18574471 .
  36. Echalier, A, Bettayeb, K, Ferandin, Y, Lozach, O, Clément, M, Valette, A et al.. Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin complex. J. Med. Chem. 2008;51 (4):737-51. doi: 10.1021/jm700940h. PubMed PMID:18232649 .
  37. Alier, KA, Endicott, JA, Stemkowski, PL, Cenac, N, Cellars, L, Chapman, K et al.. Intrathecal administration of proteinase-activated receptor-2 agonists produces hyperalgesia by exciting the cell bodies of primary sensory neurons. J. Pharmacol. Exp. Ther. 2008;324 (1):224-33. doi: 10.1124/jpet.107.129171. PubMed PMID:17921188 .
  38. Bettayeb, K, Tirado, OM, Marionneau-Lambot, S, Ferandin, Y, Lozach, O, Morris, JC et al.. Meriolins, a new class of cell death inducing kinase inhibitors with enhanced selectivity for cyclin-dependent kinases. Cancer Res. 2007;67 (17):8325-34. doi: 10.1158/0008-5472.CAN-07-1826. PubMed PMID:17804748 .
  39. Marchetti, F, Sayle, KL, Bentley, J, Clegg, W, Curtin, NJ, Endicott, JA et al.. Structure-based design of 2-arylamino-4-cyclohexylmethoxy-5-nitroso-6-aminopyrimidine inhibitors of cyclin-dependent kinase 2. Org. Biomol. Chem. 2007;5 (10):1577-85. doi: 10.1039/b703241b. PubMed PMID:17571187 .
  40. Trempe, JF, Endicott, JA. Structural biology: pass the protein. Nature. 2007;445 (7126):375-6. doi: 10.1038/nature05564. PubMed PMID:17220873 .
  41. Welburn, JP, Tucker, JA, Johnson, T, Lindert, L, Morgan, M, Willis, A et al.. How tyrosine 15 phosphorylation inhibits the activity of cyclin-dependent kinase 2-cyclin A. J. Biol. Chem. 2007;282 (5):3173-81. doi: 10.1074/jbc.M609151200. PubMed PMID:17095507 .
  42. Pratt, DJ, Bentley, J, Jewsbury, P, Boyle, FT, Endicott, JA, Noble, ME et al.. Dissecting the determinants of cyclin-dependent kinase 2 and cyclin-dependent kinase 4 inhibitor selectivity. J. Med. Chem. 2006;49 (18):5470-7. doi: 10.1021/jm060216x. PubMed PMID:16942020 .
  43. Griffin, RJ, Henderson, A, Curtin, NJ, Echalier, A, Endicott, JA, Hardcastle, IR et al.. Searching for cyclin-dependent kinase inhibitors using a new variant of the cope elimination. J. Am. Chem. Soc. 2006;128 (18):6012-3. doi: 10.1021/ja060595j. PubMed PMID:16669651 .
  44. Lowe, ED, Hasan, N, Trempe, JF, Fonso, L, Noble, ME, Endicott, JA et al.. Structures of the Dsk2 UBL and UBA domains and their complex. Acta Crystallogr. D Biol. Crystallogr. 2006;62 (Pt 2):177-88. doi: 10.1107/S0907444905037777. PubMed PMID:16421449 .
  45. Macdonald, N, Welburn, JP, Noble, ME, Nguyen, A, Yaffe, MB, Clynes, D et al.. Molecular basis for the recognition of phosphorylated and phosphoacetylated histone h3 by 14-3-3. Mol. Cell. 2005;20 (2):199-211. doi: 10.1016/j.molcel.2005.08.032. PubMed PMID:16246723 .
  46. Sasaki, T, Funakoshi, M, Endicott, JA, Kobayashi, H. Budding yeast Dsk2 protein forms a homodimer via its C-terminal UBA domain. Biochem. Biophys. Res. Commun. 2005;336 (2):530-5. doi: 10.1016/j.bbrc.2005.08.126. PubMed PMID:16140271 .
  47. Trempe, JF, Brown, NR, Lowe, ED, Gordon, C, Campbell, ID, Noble, ME et al.. Mechanism of Lys48-linked polyubiquitin chain recognition by the Mud1 UBA domain. EMBO J. 2005;24 (18):3178-89. doi: 10.1038/sj.emboj.7600797. PubMed PMID:16138082 PubMed Central PMC1224687.
  48. Welburn, JP, Endicott, JA. Inhibition of the cell cycle with chemical inhibitors: a targeted approach. Semin. Cell Dev. Biol. 2005;16 (3):369-81. doi: 10.1016/j.semcdb.2005.02.008. PubMed PMID:15840445 .
  49. Pratt, DJ, Endicott, JA, Noble, ME. The role of structure in kinase-targeted inhibitor design. Curr Opin Drug Discov Devel. 2004;7 (4):428-36. . PubMed PMID:15338952 .
  50. Hardcastle, IR, Arris, CE, Bentley, J, Boyle, FT, Chen, Y, Curtin, NJ et al.. N2-substituted O6-cyclohexylmethylguanine derivatives: potent inhibitors of cyclin-dependent kinases 1 and 2. J. Med. Chem. 2004;47 (15):3710-22. doi: 10.1021/jm0311442. PubMed PMID:15239650 .
  51. Noble, ME, Endicott, JA, Johnson, LN. Protein kinase inhibitors: insights into drug design from structure. Science. 2004;303 (5665):1800-5. doi: 10.1126/science.1095920. PubMed PMID:15031492 .
  52. Sayle, KL, Bentley, J, Boyle, FT, Calvert, AH, Cheng, Y, Curtin, NJ et al.. Structure-based design of 2-arylamino-4-cyclohexylmethyl-5-nitroso-6-aminopyrimidine inhibitors of cyclin-dependent kinases 1 and 2. Bioorg. Med. Chem. Lett. 2003;13 (18):3079-82. doi: 10.1016/s0960-894x(03)00651-6. PubMed PMID:12941338 .
  53. Mesguiche, V, Parsons, RJ, Arris, CE, Bentley, J, Boyle, FT, Curtin, NJ et al.. 4-Alkoxy-2,6-diaminopyrimidine derivatives: inhibitors of cyclin dependent kinases 1 and 2. Bioorg. Med. Chem. Lett. 2003;13 (2):217-22. doi: 10.1016/s0960-894x(02)00884-3. PubMed PMID:12482427 .
  54. Davies, TG, Bentley, J, Arris, CE, Boyle, FT, Curtin, NJ, Endicott, JA et al.. Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor. Nat. Struct. Biol. 2002;9 (10):745-9. doi: 10.1038/nsb842. PubMed PMID:12244298 .
  55. Davies, TG, Pratt, DJ, Endicott, JA, Johnson, LN, Noble, ME. Structure-based design of cyclin-dependent kinase inhibitors. Pharmacol. Ther. ;93 (2-3):125-33. doi: 10.1016/s0163-7258(02)00182-1. PubMed PMID:12191605 .
  56. Johnson, LN, De Moliner, E, Brown, NR, Song, H, Barford, D, Endicott, JA et al.. Structural studies with inhibitors of the cell cycle regulatory kinase cyclin-dependent protein kinase 2. Pharmacol. Ther. ;93 (2-3):113-24. doi: 10.1016/s0163-7258(02)00181-x. PubMed PMID:12191604 .
  57. Gibson, AE, Arris, CE, Bentley, J, Boyle, FT, Curtin, NJ, Davies, TG et al.. Probing the ATP ribose-binding domain of cyclin-dependent kinases 1 and 2 with O(6)-substituted guanine derivatives. J. Med. Chem. 2002;45 (16):3381-93. doi: 10.1021/jm020056z. PubMed PMID:12139449 .
  58. Lawrie, AM, Tito, P, Hernandez, H, Brown, NR, Robinson, CV, Endicott, JA et al.. Xenopus phospho-CDK7/cyclin H expressed in baculoviral-infected insect cells. Protein Expr. Purif. 2001;23 (2):252-60. doi: 10.1006/prep.2001.1504. PubMed PMID:11676600 .
  59. Davies, TG, Tunnah, P, Meijer, L, Marko, D, Eisenbrand, G, Endicott, JA et al.. Inhibitor binding to active and inactive CDK2: the crystal structure of CDK2-cyclin A/indirubin-5-sulphonate. Structure. 2001;9 (5):389-97. doi: 10.1016/s0969-2126(01)00598-6. PubMed PMID:11377199 .
  60. Arris, CE, Boyle, FT, Calvert, AH, Curtin, NJ, Endicott, JA, Garman, EF et al.. Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles. J. Med. Chem. 2000;43 (15):2797-804. doi: 10.1021/jm990628o. PubMed PMID:10956187 .
  61. Endicott, JA, Noble, ME, Tucker, JA. Cyclin-dependent kinases: inhibition and substrate recognition. Curr. Opin. Struct. Biol. 1999;9 (6):738-44. doi: 10.1016/s0959-440x(99)00038-x. PubMed PMID:10607671 .
  62. Brown, NR, Noble, ME, Endicott, JA, Johnson, LN. The structural basis for specificity of substrate and recruitment peptides for cyclin-dependent kinases. Nat. Cell Biol. 1999;1 (7):438-43. doi: 10.1038/15674. PubMed PMID:10559988 .
  63. Hoessel, R, Leclerc, S, Endicott, JA, Nobel, ME, Lawrie, A, Tunnah, P et al.. Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nat. Cell Biol. 1999;1 (1):60-7. doi: 10.1038/9035. PubMed PMID:10559866 .
  64. Noble, ME, Endicott, JA. Chemical inhibitors of cyclin-dependent kinases: insights into design from X-ray crystallographic studies. Pharmacol. Ther. ;82 (2-3):269-78. doi: 10.1016/s0163-7258(98)00051-5. PubMed PMID:10454204 .
  65. Brown, NR, Noble, ME, Lawrie, AM, Morris, MC, Tunnah, P, Divita, G et al.. Effects of phosphorylation of threonine 160 on cyclin-dependent kinase 2 structure and activity. J. Biol. Chem. 1999;274 (13):8746-56. doi: 10.1074/jbc.274.13.8746. PubMed PMID:10085115 .
  66. Endicott, JA, Noble, ME. Structural principles in cell-cycle control: beyond the CDKs. Structure. 1998;6 (5):535-41. doi: 10.1016/s0969-2126(98)00055-0. PubMed PMID:9634691 .
  67. Noble, ME, Endicott, JA, Brown, NR, Johnson, LN. The cyclin box fold: protein recognition in cell-cycle and transcription control. Trends Biochem. Sci. 1997;22 (12):482-7. doi: 10.1016/s0968-0004(97)01144-4. PubMed PMID:9433129 .
  68. Lawrie, AM, Noble, ME, Tunnah, P, Brown, NR, Johnson, LN, Endicott, JA et al.. Protein kinase inhibition by staurosporine revealed in details of the molecular interaction with CDK2. Nat. Struct. Biol. 1997;4 (10):796-801. doi: 10.1038/nsb1097-796. PubMed PMID:9334743 .
  69. Brown, NR, Noble, ME, Endicott, JA, Garman, EF, Wakatsuki, S, Mitchell, E et al.. The crystal structure of cyclin A. Structure. 1995;3 (11):1235-47. doi: 10.1016/s0969-2126(01)00259-3. PubMed PMID:8591034 .
  70. Endicott, JA, Nurse, P. The cell cycle and suc1: from structure to function?. Structure. 1995;3 (4):321-5. doi: 10.1016/s0969-2126(01)00162-9. PubMed PMID:7613861 .
  71. Endicott, JA, Noble, ME, Garman, EF, Brown, N, Rasmussen, B, Nurse, P et al.. The crystal structure of p13suc1, a p34cdc2-interacting cell cycle control protein. EMBO J. 1995;14 (5):1004-14. . PubMed PMID:7889931 PubMed Central PMC398172.
  72. Endicott, JA, Nurse, P, Johnson, LN. Mutational analysis supports a structural model for the cell cycle protein kinase p34. Protein Eng. 1994;7 (2):243-53. doi: 10.1093/protein/7.2.243. PubMed PMID:8170927 .
  73. Endicott, JA, Sarangi, F, Ling, V. Complete cDNA sequences encoding the Chinese hamster P-glycoprotein gene family. DNA Seq. 1991;2 (2):89-101. doi: 10.3109/10425179109039677. PubMed PMID:1685679 .
  74. Endicott, JA, Ling, V. The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu. Rev. Biochem. 1989;58 :137-71. doi: 10.1146/annurev.bi.58.070189.001033. PubMed PMID:2570548 .
  75. Endicott, JA, Juranka, PF, Sarangi, F, Gerlach, JH, Deuchars, KL, Ling, V et al.. Simultaneous expression of two P-glycoprotein genes in drug-sensitive Chinese hamster ovary cells. Mol. Cell. Biol. 1987;7 (11):4075-81. doi: 10.1128/mcb.7.11.4075. PubMed PMID:2893255 PubMed Central PMC368078.
  76. Gerlach, JH, Endicott, JA, Juranka, PF, Henderson, G, Sarangi, F, Deuchars, KL et al.. Homology between P-glycoprotein and a bacterial haemolysin transport protein suggests a model for multidrug resistance. Nature. ;324 (6096):485-9. doi: 10.1038/324485a0. PubMed PMID:2878368 .
Search PubMed